Clinical utility of Glypican-3 in hepatocellular carcinoma

International Journal of Integrative Biology

Volumn 10, Issue 1, 2010, Pages 41-47

  Youssef, Mona F ^a   El Sharkawy, Sonia L ^b   Abbas, Naglaa F ^b   El Shinnawy, Samah E ^a   El Hadidi, Eman S ^a   Shahin, Rania S ^a   Shalaby, Hend A ^c  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c AIN SHAMS UNIVERSITY HOSPITAL   (Egypt)

Author keywords

Alpha fetoprotein; Glypican 3; Hepatocellular carcinoma; Immunohistochemistry; PCR

Indexed keywords

ALPHA FETOPROTEIN; GLYPICAN 3; MESSENGER RNA;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; EARLY DIAGNOSIS; ENZYME IMMUNOASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 77956241489     PISSN: 09738363     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Anatelli FL, Chuano ST, et al. (2008) Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am. J. Clin. Pathol., 130(2): 219-23.
2. Befeler AS and Di Bisceglie AM (2002) Hepatocellular carcinoma: Diagnosis and treatment. Gastroenterology, 122: 1609-19.
3. Capurro M, Wanless IR, et al. (2003) Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology, 125: 89-97.
4. Capurro MI, Xiang YY, et al. (2005) Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res., 65: 6245-6254.
5. Cheng W, Tseng CJ, et al. (2008) Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis, 29 (7): 1319-26.
6. Coston W.M, Loera S, et al. (2008) Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am. J. Surg. Pathol., 32(3): 433-44.
7. Dina KH and Kumarasen CM (2009) Glycipan-3: A novel diagnostic marker for hepatocellular carcinoma and more. Advances in Anatomic Pathology, 16 (2): 125-129.
8. Edmonson HA and Steiner PE (1954) Primary carcinoma of the liver: A study of 100 cases among 48900 necropsies. Cancer, 7: 462-503.
9. Eisuke Y, Takashi K, et al. (2010) Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatology Research, 40 (5): 477-485.
10. Filmus J and Capurro M (2004) Glycipan-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol. Diagn., 8(4): 207-12.
11. Gebo KA, Chander G, et al. (2002) Screening tests for hepatocellular carcinoma in patients with chronic hepatitis: A systematic review Hepatology, 36: S84-92.
12. Hayashi E, Motomura Y, et al. (2009) Detection of Glycipan-3-specific TCLs in chronic hepatitis and liver cirrhosis. Oncol. Rep., 22(1): 149-154.
13. Hippo Y, Watanabe K, et al. (2004) Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res., 64: 2418-2423.
14. Jackubovic BD and Jothy S (2007) Glycipan-3: From the mutations of simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Experimental and Molecular Pathology, 82: 184-9.
15. Laurent-Puig P, Legoix P, et al. (2001) Genetic alterations associated with hepatocellular carcinoma define distinct pathways of hepatocarcinogenesis. Gastroenterology, 120: 1763-73.
16. Li BD, Zhao QC, et al. (2006) Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells. Zhonshua Wai Ke Za Zhi, 44(7): 458-62.
17. Ligato S, Mandich D, et al. (2008) Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: An immunocytochemical study. Mod. Pathol, 21(5): 626-31.
18. Liovet JM, Chen Y, et al. (2006) A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroentrology, 131: 1758-1767.
19. Motomura Y, Senju S, et al. (2006) Embryonic stem cell-derived dendritic cells expressing glypican-3: A recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res., 66: 2414-2422.
20. Nakatsura T, Yoshitake Y, et al. (2003) Glypican-3: Overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem. Biophys. Res. Commun., 306: 16-25.
21. Nakatsura T and Nishimura Y (2005) Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs, 19(2): 71-7.
22. Nishimura Y, Nakatsura T, et al. (2008) Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi, 31 (5): 383-91.
23. Poon RTP, Fan ST, Lo CM, et al. (1999) Intrahepatic recurrence after curative resection of hepatocellular carcinoma: Long term results of treatment and prognostic factors. Ann. Surg., 229: 216-22.
24. Rustgi VK (1987) Epidemiology of hepatocellular carcinoma. Gastroenterol. Clin. North Am., 16: 545-551.
25. Sakamoto M, Mori T, et al. (2008) Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma. Intervirology, 51(S1): 42-5.
26. Shafizadeh N, Ferrell LP, et al. (2008) Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod. Pathol., 21(8): 1011-8.
27. Shirakawa H, Suzuki H, et al. (2009) Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci., 100(8): 1403-1407.
28. Sung YK, Hwang SY, et al. (2003) Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci., 94(3): 259-262.
29. Tang ZY, Zhou XD, et al. (1999) Surgical treatment of hepatocellular carcinoma and related basic research with special reference to recurrence and metastasis. Chin. Med., 112: 887-91.
30. Thorgeirsson SS and Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet., 31: 339-46.
31. Vollmer CM, Eilber FC, et al. (1999) Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res., 59: 3064-3067.
32. Wang XY, Degos F, et al. (2006) Glypican-3 expression in hepatocellular tumors: Diagnostic value for pre-neoplastic lesions and hepatocellular carcinomas. Human Pathol., 37: 1435-41.
33. Wang HL, Florencia A, et al. (2008) Glypican-3 as a Useful Diagnostic Marker That Distinguishes Hepatocellular Carcinoma From Benign Hepatocellular Mass Lesions. Arch. Pathol. Lab. Med., 132: 1723.
34. Wright AS, Mahvi DM, et al. (2003) Minimally invasive approaches in management of hepatic tumors. Surg. Teehnol. Int., 11: 144-53.
35. Xiao YW, Francoise D, et al. (2006) Glypican-3 expression in hepatocellular tumors: Diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Human Pathol., 37: 1435-1441.
36. Yajnauchi N, Watanabe A, et al. (2005) The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod. Pathol., 18: 1591-1598.
37. Yanaga K (2004) Current status of hepatic resection for hepatocellular carcinoma. J. Gastroenterol., 39: 919-26.
38. Zhou L, Liu J, et al. (2006) Markers for detection of hepatocellular carcinoma. World J. Gastroenterol., 12(8): 1175-81.